11.07.2005 – 17:40
PharmaMar Reinforces its Clinical Development Team With the Appointment of Dr Pedro Santabárbara
- In his Previous Position he was Vice President, Clinical Research Oncology at OSI Pharmaceuticals in the US
PharmaMar announced today the appointment of Dr. Pedro Santabárbara as Senior Director of the Clinical Development Department. Dr. Santabárbara is a medical oncologist trained at the University Hospital of Barcelona, with wide international experience in the pharmaceutical and biotechnology industry, including management positions in Clinical Oncology Research Departments at Bristol Myers, Rhône Poulenc Rhorer, Ilex Oncology and OSI Pharmaceuticals. For the last 13 years he has been closely involved in the clinical development and approval of the important drugs currently used in the treatment of cancer, such as Taxotere, Campath and Tarceva.
He will focus on the clinical development and regulatory strategies for all compounds in PharmaMar`s clinical pipeline.
Dr. Miguel Ángel Izquierdo, PharmaMar's Director of the Clinical Development Area, commented: "Dr. Pedro Santabárbara's appointment is excellent news for PharmaMar. His experience in key positions in multinational companies and his direct involvement in the approval of various anti-tumour drugs is very valuable for us. In addition, his appointment is very timely since we are now at the clinical development stage for five drugs and are preparing the registration dossier for Yondelis for the treatment of soft tissue sarcoma."
Currently, the Clinical Development Area at PharmaMar has over 50 professionals, including a team of eight medical oncologists. In May this year, Dr Cesar Picó joined PharmaMar as Director of Clinical Oncology. He has more than 13 years of experience in several University Hospitals as well as in the Pharmaceutical Industry as Medical Oncology Consultant at Pharmacia Upjohn and subsequently at Pfizer. He is also a founding member of the Spanish Breast Cancer Research Group (GEICAM).
These new appointments represent a considerable strengthening of the PharmaMar Clinical Development Team.
PharmaMar is the world's leading biopharmaceutical companies in advancing cancer care through the discovery and development of innovative marine-derived medicines. PharmaMar's clinical portfolio currently includes: YONDELIS(TM) (co-developed with Johnson & Johnson Pharmaceutical Research & Development) in Phase III clinical trials; it is also designated Orphan Drug for Soft Tissue Sarcomas by the European Commission (E.C.) in 2001 and by the FDA in 2004, and Orphan Drug for ovarian cancer by the E.C. in 2003 and by the FDA in 2005. It also features Aplidin(R), in Phase II, designated Orphan Drug for acute lymphoblastic leukaemia by the E.C. in 2003 and by the FDA in 2004, and for multiple myeloma by the FDA and the EC in 2004; as well as Kahalalide F in Phase II, and ES-285 and Zalypsis(R) in Phase I clinical trials.
PharmaMar, based in Madrid, Spain, is a subsidiary of the Zeltia Group (Spanish stock exchange, ZEL).
@@start.t1@@ For more information, contact:
Media: Lola Casals, PharmaMar Communication (tel.: +34-91-846-6000)
Investors: Catherine Moukheibir, Zeltia Capital Markets Operations
MADRID, July 11 /PRNewswire/ --
This press release is also available in the News section on PharmaMar's web site: http://www.pharmamar.com/en/press/
ots Originaltext: PharmaMar
Im Internet recherchierbar: http://www.presseportal.de
For more information, contact: Media: Lola Casals, PharmaMar
Communication (tel.: +34-91-846-6000); Investors: Catherine
Moukheibir, Zeltia Capital Markets Operations; (tel.:
Original-Content von: PharmaMar, übermittelt durch news aktuell